Page 3 - Hiv Prep News Today

Can the US reach its goal to end the HIV/AIDS epidemic? The Biden Administration is putting a lot of $$ behind the effort.

The risk of kidney-related adverse events among patients receiving tenofovir disoproxil fumarate-based oral HIV pre-exposure prophylaxis is small, a systematic review and meta-analysis revealed.

Physicians may be missing opportunities to discuss HIV prevention with their sexually active patients.

Heterosexual sex accounts for 23% of new HIV diagnoses, but this report shows that PrEP awareness among at-risk heterosexual adults is low, particularly among certain groups.

Patients and providers anxiously await distribution of long-acting injectable PrEP, but the ante might be too high.

One year after the World Health Organization recommended a vaginal ring to protect women from HIV following years of research — some done in the US — the ring will not be coming to US clinics. Heres why.

Long-acting HIV PrEP approved but its unclear if healthcare systems are ready.

New NICE guidelines are to recommend offering pre-exposure HIV prophylaxis for high-risk groups for the first time, bringing guidance in-line with wider Government policy.

Since the FDA approved the first pill to prevent HIV in 2012, the medication has been slow to move out of sexual health and infectious disease practices. The new guidelines ask clinicians to step up.

The HIV prevention pill has been available since 2012, but use of the pill is significantly lower among Black people in general, including Black women.